These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32119867)

  • 41. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.
    Piekarz RL; Robey R; Sandor V; Bakke S; Wilson WH; Dahmoush L; Kingma DM; Turner ML; Altemus R; Bates SE
    Blood; 2001 Nov; 98(9):2865-8. PubMed ID: 11675364
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
    Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
    Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HDAC-mediated deacetylation of KLF5 associates with its proteasomal degradation.
    Tao R; Zhang B; Li Y; King JL; Tian R; Xia S; Schiavon CR; Dong JT
    Biochem Biophys Res Commun; 2018 Jun; 500(3):777-782. PubMed ID: 29679567
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors.
    Li Y; Li X; Fan G; Fukushi J; Matsumoto Y; Iwamoto Y; Zhu Y
    Cancer Lett; 2012 Jul; 320(1):14-22. PubMed ID: 22266186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
    Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
    Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma.
    Trager MH; Geskin LJ
    G Ital Dermatol Venereol; 2019 Dec; 154(6):681-695. PubMed ID: 31859467
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.
    Sung JJ; Ververis K; Karagiannis TC
    J Photochem Photobiol B; 2014 Feb; 131():104-12. PubMed ID: 24518645
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
    Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
    J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
    Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acetylation of HDAC1 and degradation of SIRT1 form a positive feedback loop to regulate p53 acetylation during heat-shock stress.
    Yang H; Yan B; Liao D; Huang S; Qiu Y
    Cell Death Dis; 2015 May; 6(5):e1747. PubMed ID: 25950477
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
    Yang Z; Shen M; Tang M; Zhang W; Cui X; Zhang Z; Pei H; Li Y; Hu M; Bai P; Chen L
    Eur J Med Chem; 2019 Sep; 178():116-130. PubMed ID: 31177073
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells.
    Reddy ND; Shoja MH; Biswas S; Nayak PG; Kumar N; Rao CM
    Chem Biol Interact; 2016 Jun; 253():112-24. PubMed ID: 27163855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.
    Borbone E; Berlingieri MT; De Bellis F; Nebbioso A; Chiappetta G; Mai A; Altucci L; Fusco A
    Oncogene; 2010 Jan; 29(1):105-16. PubMed ID: 19802013
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HDAC inhibitor DWP0016 activates p53 transcription and acetylation to inhibit cell growth in U251 glioblastoma cells.
    Jin H; Liang L; Liu L; Deng W; Liu J
    J Cell Biochem; 2013 Jul; 114(7):1498-509. PubMed ID: 23297003
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Histone Deacetylase 1 Is Essential for Rod Photoreceptor Differentiation by Regulating Acetylation at Histone H3 Lysine 9 and Histone H4 Lysine 12 in the Mouse Retina.
    Ferreira RC; Popova EY; James J; Briones MR; Zhang SS; Barnstable CJ
    J Biol Chem; 2017 Feb; 292(6):2422-2440. PubMed ID: 28028172
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
    Gatla HR; Zou Y; Uddin MM; Singha B; Bu P; Vancura A; Vancurova I
    J Biol Chem; 2017 Mar; 292(12):5043-5054. PubMed ID: 28167529
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.
    Chou CF; Hsieh YH; Grubbs CJ; Atigadda VR; Mobley JA; Dummer R; Muccio DD; Eto I; Elmets CA; Garvey WT; Chang PL
    J Dermatol Sci; 2018 Jun; 90(3):343-356. PubMed ID: 29599065
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systemic therapy of cutaneous T-cell lymphoma (CTCL).
    Alpdogan O; Kartan S; Johnson W; Sokol K; Porcu P
    Chin Clin Oncol; 2019 Feb; 8(1):10. PubMed ID: 30818958
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.
    Huang HL; Peng CY; Lai MJ; Chen CH; Lee HY; Wang JC; Liou JP; Pan SL; Teng CM
    Oncotarget; 2015 Mar; 6(7):4976-91. PubMed ID: 25669976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.